What is the market cap of Handok?

The market capitalisation of Handok was ₩115B at the close on Oct 27, 2026.

Who are the largest shareholders of Handok?

According to the latest official filings, the largest reported holders are Kim Young-jin (42.15%, as of Sep 10, 2026); Y&S International (18.11%, as of Jun 4, 2026); IBK Capital (14.52%, as of Dec 16, 2024).

When is the next earnings report from Handok?

Korean companies rarely announce results dates in advance. Based on when Handok filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.

Does the National Pension Service own Handok?

Yes. The National Pension Service held 0.44% of Handok shares as of Dec 31, 2025.

KOSPI · 002390 · Biotech & Pharma · ₩002390

Handok한독

002390 · KOSPI · ₩002390 · 한독

₩8,320▲ ₩80 (0.97%)End-of-day · Oct 27, 2026 · End-of-day prices.

Trade

Price · 1Y −28.21%

Market cap: ₩115B
Enterprise value: ₩466B
P/E: —
P/B: 0.5×
Dividend yield: 2.4%
ROE: −3.7%
Net margin: −1.7%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−31.5% from the high

₩6,460Today: ₩8,250 – ₩8,670₩12,150

Returns

1W−2.2%
1M−0.7%
3M−4.9%
6M−20.4%
YTD−25.7%
1Y−28.2%

Volume today: 2,911; 0.6× the 20-day average
Traded today: ₩25M
Listed shares: 13,763,533
EPS (12 months): −₩681; Earnings yield −8.2%

Sell Buy

AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

X f WA TG r/in @

Signals

Quiet

BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
SentimentMixedNews: Filings are routine corporate notices, with one value-up plan. Community: 0 bullish, 0 bearish posts this week.
MomentumFlat-0.6% over the last month; the price is below its 20-day average.
News impactLow5 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Handok stock overview

Handok (한독, KRX: 002390) is listed on KOSPI, in the Biotech & Pharma sector. Handok is a Korean pharmaceutical company founded in 1954 that engages in manufacturing and selling prescription and over-the-counter medicines, along with medical devices, health supplements, contract manufacturing, and real estate leasing. Its shares closed at ₩8,320 on Oct 27, 2026, up 0.97% on the day, giving it a market value of ₩115B.

Market cap: ₩115B
Sector: Biotech & Pharma
Latest price change: +0.97%
As of: Oct 27, 2026
Main business: Handok is a Korean pharmaceutical company founded in 1954 that engages in manufacturing and selling prescription and over-the-counter medicines, along with medical devices, health supplements, contract manufacturing, and real estate leasing.

Quick answers about Handok

What does Handok do?: Handok is a Korean pharmaceutical company founded in 1954 that engages in manufacturing and selling prescription and over-the-counter medicines, along with medical devices, health supplements, contract manufacturing, and real estate leasing. Its main products include diabetes treatments Amaryl and Tenelia, and Ketotop, Festal, and Triteace, and it sells diagnostic devices and nutrition products to consumers and healthcare customers. The company is headquartered in Seoul, operates a factory in Eumseong in Chungcheongbuk-do, a research institute in Seoul's Magok district, and regional sales offices across Korea.
What is the market cap of Handok?: The market capitalisation of Handok was ₩115B at the close on Oct 27, 2026.
Who are the largest shareholders of Handok?: According to the latest official filings, the largest reported holders are Kim Young-jin (42.15%, as of Sep 10, 2026); Y&S International (18.11%, as of Jun 4, 2026); IBK Capital (14.52%, as of Dec 16, 2024).
When is the next earnings report from Handok?: Korean companies rarely announce results dates in advance. Based on when Handok filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Does the National Pension Service own Handok?: Yes. The National Pension Service held 0.44% of Handok shares as of Dec 31, 2025.

Company profile

Handok is a Korean pharmaceutical company founded in 1954 that engages in manufacturing and selling prescription and over-the-counter medicines, along with medical devices, health supplements, contract manufacturing, and real estate leasing. Its main products include diabetes treatments Amaryl and Tenelia, and Ketotop, Festal, and Triteace, and it sells diagnostic devices and nutrition products to consumers and healthcare customers. The company is headquartered in Seoul, operates a factory in Eumseong in Chungcheongbuk-do, a research institute in Seoul's Magok district, and regional sales offices across Korea.

Written by AI from the company's latest annual report.

Korean name: 한독
Sector: Biotech & Pharma
Themes: Pharmaceuticals
CEO: 김영진, 백진기
Founded: Jul 1954
Listed: Jun 1976
Listed shares: 13,763,533
Fiscal year ends: Month 12
Website: www.handok.co.kr

Similar companies

Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
Celltrion068270 · ₩44T₩188,600−0.74%
Alteogen196170 · ₩15T₩218,5000.00%
Yuhan000100 · ₩5.9T₩80,000−2.08%
SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
HLB028300 · ₩5.3T₩39,900+1.66%
Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%

Recent filings

See all

[Amended] Notice of Stock Purchase Option GrantOct 27, 2026
[Amended] Notice of Stock Purchase Option GrantOct 27, 2026
Corporate value-up planOct 26, 2026
[Amended] Notice of Stock Purchase Option GrantOct 26, 2026
Notice on Grant of Stock Purchase OptionsOct 26, 2026

Titles in Korean until English translations are added.

Key numbers

Volume: 2,911
Traded value: ₩25M
Day range: ₩8,250 – ₩8,670
Revenue (TTM): ₩561B
Operating margin: 1.5%
Net margin: −1.7%
ROE: −3.7%
Revenue growth (last year): +5.5%
Liabilities to equity: 206%
Foreign ownership: 2.27%
Short balance: 0.16%

Trailing 12 months from filed financial statements, as of H1 2026.

Who owns Handok?

See all

Kim Young-jin김영진5% report42.15%5.8M sharesas of Sep 10, 2026
Y&S International와이앤에스인터내셔날10%이상주주Insider report18.11%2.5M sharesas of Jun 4, 2026
IBK Capital아이비케이캐피탈5% report14.52%2.3M sharesas of Dec 16, 2024
National Pension Service국민연금공단NPS year-endNPS 5% report0.44%as of Dec 31, 2025
Dimensional Emerging Markets Core Equity 2 ETFDimensional ETF TrustN-PORT0.09%12.7K shares≈ $79.9Kas of Jul 31, 2026
EMERGING MARKETS CORE EQUITY 2 PORTFOLIODFA INVESTMENT DIMENSIONS GROUP INCN-PORT0.06%7.8K shares≈ $48.7Kas of Jul 31, 2026

From official filings only: 5% reports and executives' and major shareholders' reports (Korea), and US funds' Form N-PORT and US managers' Form 13F (ADRs) reports. Each holder shows its latest report and the date it was as of; the same holder in two reports is shown once.

Institutions holding 5% or more

All institutions →

IBK Capital CorporationEst. avg cost ₩12,34014.52%−32.6%

Only holdings of 5% or more are disclosed. We add up every reported trade (shares × the price in the filing, or that day's close when the filing gives none) to estimate an average cost, then value the stake at the latest close. Shares held before the first reported trade count at that day's close. It is an estimate, not the institution's real return.

National Pension Service

0.44% of shares

Year-end 2025 holding

Worth ₩700M

NPS stake by year-end

NPS year-end holdings, published annually.

Also known as: Handok / 한독 / 002390 / KRX:002390

Source: KRX statistical information